Pallavi N Mane, Digambar Dg, Pruthviraj P Ugale, Abhijit Shekhar, Jibi Varghese, Anupama M Bathe, Abhilasha C. Lagad
{"title":"Madhusudan Vati和Arogyavardhini Vati对Prameha的增效作用研究,特别参考2型糖尿病","authors":"Pallavi N Mane, Digambar Dg, Pruthviraj P Ugale, Abhijit Shekhar, Jibi Varghese, Anupama M Bathe, Abhilasha C. Lagad","doi":"10.47552/ijam.v14i2.3302","DOIUrl":null,"url":null,"abstract":"Prameha (Diabetes mellitus) is an age long disease known from vedic period and now it is a leading lifestyle disorder. Diabetes mellitus is a group of metabolic syndromes of fat, protein and carbohydrate which is due to absolute or relative deficiency of insulin, characterized by hyperglycemia over a prolonged period with polyuria, polydipsia, and polyphagia like symptoms. The estimates in 2019 showed that 77 million individuals had diabetes in India, which is expected to rise to over 134 million by 2045. It has turned out to be the biggest “silent killer” in today’s world. This is an Open label Comparative clinical study with pre-test and post-test design where in 60 patients suffering from Prameha (type 2 DM) of either gender between the age group of 25 to 75 years were randomly selected and grouped into Group A and Group B. The 30 patients in Group A were treated with Arogyavardhini vati & Madhusudhan vati with Metformin (500 mg) and Glimepiride (1mg) BD. Group B of 30 patients were given Metformin (500mg) and Glimepiride (1 mg) for 120 days. Results obtained in subjective and objective parameters were analyzed for the statistical significance by adapting paired T test, unpaired T test, Mann-Whitney Z and Wilcoxon Signed Ranks Test Z. The study revealed that Group A was found to be more effective in bringing symptomatic relief and improving biochemical markers in the patients of Prameha. ","PeriodicalId":13751,"journal":{"name":"International Journal of Ayurvedic Medicine","volume":" ","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Study of add on effect of Madhusudan Vati and Arogyavardhini Vati in Prameha with special reference to Type 2 Diabetes Mellitus\",\"authors\":\"Pallavi N Mane, Digambar Dg, Pruthviraj P Ugale, Abhijit Shekhar, Jibi Varghese, Anupama M Bathe, Abhilasha C. Lagad\",\"doi\":\"10.47552/ijam.v14i2.3302\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Prameha (Diabetes mellitus) is an age long disease known from vedic period and now it is a leading lifestyle disorder. Diabetes mellitus is a group of metabolic syndromes of fat, protein and carbohydrate which is due to absolute or relative deficiency of insulin, characterized by hyperglycemia over a prolonged period with polyuria, polydipsia, and polyphagia like symptoms. The estimates in 2019 showed that 77 million individuals had diabetes in India, which is expected to rise to over 134 million by 2045. It has turned out to be the biggest “silent killer” in today’s world. This is an Open label Comparative clinical study with pre-test and post-test design where in 60 patients suffering from Prameha (type 2 DM) of either gender between the age group of 25 to 75 years were randomly selected and grouped into Group A and Group B. The 30 patients in Group A were treated with Arogyavardhini vati & Madhusudhan vati with Metformin (500 mg) and Glimepiride (1mg) BD. Group B of 30 patients were given Metformin (500mg) and Glimepiride (1 mg) for 120 days. Results obtained in subjective and objective parameters were analyzed for the statistical significance by adapting paired T test, unpaired T test, Mann-Whitney Z and Wilcoxon Signed Ranks Test Z. The study revealed that Group A was found to be more effective in bringing symptomatic relief and improving biochemical markers in the patients of Prameha. \",\"PeriodicalId\":13751,\"journal\":{\"name\":\"International Journal of Ayurvedic Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2023-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Ayurvedic Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.47552/ijam.v14i2.3302\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Ayurvedic Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47552/ijam.v14i2.3302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
Prameha(糖尿病)是一种从妊娠期开始就被认为是一种长期疾病,现在它是一种主要的生活方式障碍。糖尿病是一组由胰岛素绝对或相对缺乏引起的脂肪、蛋白质和碳水化合物代谢综合征,其特征是长期高血糖,伴有多尿、多饮和多食样症状。2019年的估计显示,印度有7700万人患有糖尿病,预计到2045年将增至1.34亿人以上。事实证明,它是当今世界最大的“无声杀手”。这是一项开放标签比较临床研究,采用试验前和试验后设计,随机选择60名年龄在25至75岁之间的Prameha(2型糖尿病)患者,分为A组和B组。A组的30名患者接受Arogyavardhini vati和Madhusudhan vati加二甲双胍(500 mg)和格列美脲(1mg)BD的治疗。B组30名患者服用二甲双胍(500mg)和格列美脲(1mg),持续120天。通过采用配对T检验、非配对T检验,Mann-Whitney Z和Wilcoxon Signed Ranks检验Z,分析主观和客观参数的结果的统计学意义。研究表明,A组在Prameha患者的症状缓解和改善生化标志物方面更有效。
The Study of add on effect of Madhusudan Vati and Arogyavardhini Vati in Prameha with special reference to Type 2 Diabetes Mellitus
Prameha (Diabetes mellitus) is an age long disease known from vedic period and now it is a leading lifestyle disorder. Diabetes mellitus is a group of metabolic syndromes of fat, protein and carbohydrate which is due to absolute or relative deficiency of insulin, characterized by hyperglycemia over a prolonged period with polyuria, polydipsia, and polyphagia like symptoms. The estimates in 2019 showed that 77 million individuals had diabetes in India, which is expected to rise to over 134 million by 2045. It has turned out to be the biggest “silent killer” in today’s world. This is an Open label Comparative clinical study with pre-test and post-test design where in 60 patients suffering from Prameha (type 2 DM) of either gender between the age group of 25 to 75 years were randomly selected and grouped into Group A and Group B. The 30 patients in Group A were treated with Arogyavardhini vati & Madhusudhan vati with Metformin (500 mg) and Glimepiride (1mg) BD. Group B of 30 patients were given Metformin (500mg) and Glimepiride (1 mg) for 120 days. Results obtained in subjective and objective parameters were analyzed for the statistical significance by adapting paired T test, unpaired T test, Mann-Whitney Z and Wilcoxon Signed Ranks Test Z. The study revealed that Group A was found to be more effective in bringing symptomatic relief and improving biochemical markers in the patients of Prameha.